CD44 and CD24 expression was evaluated by double-staining immunohistochemistry technique in 165 cases of breast cancer tissues, and the cancer cell with CD44+/CD24-/low phenotype might be considered as BT-IC. This evidence concerns the gene CD24 and breast carcinoma.